CASE REPORTS
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Sebaceous carcinoma of the eyelids: a review of 21 cases.

BACKGROUND: Sebaceous carcinoma is a malignant neoplasm that arises from the sebaceous glands and occurs most often in the eyelids. A tumour diameter exceeding 10mm indicates a grave prognosis. However, thus far, no study has used the T classification of the tumour, node, metastasis (TNM) staging system to determine the prognosis. In this article, we studied the management and outcomes of sebaceous carcinoma using the T classification.

METHODS: We report our experience of sebaceous carcinoma of the eyelids in 21 patients between December 1979 and December 2003. We employed the method of T classification and assessed the management and clinical outcomes in patients with sebaceous carcinoma of the eyelids.

RESULTS: The sample included three T1, six T2, five T3, and seven T4 cases. All the cases were managed by surgery. The follow-up periods ranged from 22 to 123 months. The mean and the median were 70.7 and 62 months, respectively. At the time of the last follow up, 12 of the 21 patients were alive. Five deaths were secondary to the tumour and four were unrelated. Most importantly, none of the T1, T2, or T3 patient deaths were secondary to the tumour. However, all the patients that died as a result of the tumour were of the T4 type. The cause-specific cumulative survival rate over five years was 78.9%; however, that of the T4 type was 42.9%.

CONCLUSION: None of the T1, T2, or T3 patients died as a result of the tumour, which indicates a good prognosis. However, the cases of the T4 type had a grave prognosis. Therefore, the T classification alone may be an important factor in determining the prognosis for sebaceous carcinoma of the eyelids.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app